PAYS enters October with an unusual tension: the sell-side is getting more bullish just as short sellers are quietly adding to their positions.
DA Davidson raised its price target on Paysign to $15 from $12 on September 30, maintaining its Buy rating. That follows Lake Street lifting its own target to $15 from $13 two weeks earlier. The consensus mean target now sits at $14.10, roughly 10% above the current price of $12.85. Both firms have been steadily ratcheting targets higher since early 2025, tracking the stock's 145%-plus year-to-date run. The bull case centres on PaySign's diversified payment solutions across healthcare and pharma, with bears pointing to concentration in the plasma donor compensation market and execution risk on new pharmaceutical campaign wins.
The short picture complicates that constructive read. Short interest has risen 51% over the past month, reaching 3.6% of the free float. The weekly pace is accelerating too: shorts added nearly 11% more exposure in the last five trading sessions alone. That level is not extreme in absolute terms, but the rate of change is worth tracking on a stock that has made such a dramatic move. Borrow conditions remain very easy. Availability has actually widened slightly on the week, with roughly 21 million shares available to lend against just 2 million short. Cost to borrow is a modest 0.41%, down slightly on the week. There is no squeeze pressure here; the shorts are building into ample liquidity.
Options positioning has shifted more defensively alongside the short rebuilding. The put/call ratio is running at 0.42, above its 20-day average of 0.35 and nearly a full standard deviation above that mean. The ratio spiked sharply from below 0.20 on September 22-23, before settling into this higher range for three consecutive sessions. The 52-week high on the PCR is 0.51, so the move is notable but not yet at the year's most cautious extreme.
The insider register adds a layer of nuance. Net insider selling over the past 90 days totals around 605,000 shares, worth roughly $6.6 million. The Chief Innovation Officer sold 150,000 shares worth over $1.9 million in two tranches on September 8 and 9, and those sales were discretionary, not under a pre-arranged 10b5-1 plan. The CFO also sold 35,000 shares in August outside of a plan. The CEO sold 150,000 shares in early August, though that was a planned 10b5-1 sale. Discretionary selling by senior executives at or near the stock's highs is the kind of signal worth noting, even if the stock's underlying momentum has remained intact. The largest holder, CEO Mark Newcomer, still controls 16.2% of shares outstanding, so the reductions are trims rather than exits.
Valuation has drifted higher on the back of the stock's run. The trailing PE has moved to 22x, up modestly over the past month. EV/EBITDA is near 16x. Those are not stretched multiples for a company growing sales at 44% year-on-year, but they leave the stock with limited margin for error if momentum slows. The EPS surprise factor scores in the 87th percentile, reflecting a track record of beating estimates. The most recent earnings event in early August produced a one-day move of 34% and a five-day follow-through of 38%, a reminder of how violently Paysign can re-rate around results.
With the next earnings print scheduled for November 6, thirty-seven days out, the positioning question sharpens. Shorts are rebuilding at elevated prices, the sell-side is lifting targets, insiders are trimming, and options traders are buying more protection than they were a week ago. What to watch is whether the short interest continues its recent monthly pace of accumulation into the print, and whether the discretionary insider selling accelerates or pauses as the stock approaches its analyst price targets.
See the live data behind this article on ORTEX.
Open PAYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
